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Abstract
Background: National Institute of Mental Health Project Accept (HIV Prevention Trials Network [HPTN] 043) is a large, Phase
III, community-randomized, HIV prevention trial conducted in 48 matched communities in Africa and Thailand. The study
intervention included enhanced community-based voluntary counseling and testing. The primary endpoint was HIV
incidence, assessed in a single, cross-sectional, post-intervention survey of .50,000 participants.
Methods: HIV rapid tests were performed in-country. HIV status was confirmed at a central laboratory in the United States.
HIV incidence was estimated using a multi-assay algorithm (MAA) that included the BED capture immunoassay, an avidity
assay, CD4 cell count, and HIV viral load.
Results: Data from Thailand was not used in the endpoint analysis because HIV prevalence was low. Overall, 7,361 HIV
infections were identified (4 acute, 3 early, and 7,354 established infections). Samples from established infections were
analyzed using the MAA; 467 MAA positive samples were identified; 29 of those samples were excluded because they
contained antiretroviral drugs. HIV prevalence was 16.5% (range at study sites: 5.93% to 30.8%). HIV incidence was 1.60%
(range at study sites: 0.78% to 3.90%).
Conclusions: In this community-randomized trial, a MAA was used to estimate HIV incidence in a single, cross-sectional
post-intervention survey. Results from this analysis were subsequently used to compare HIV incidence in the control and
intervention communities.
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Introduction
Project Accept (HIV Prevention Trials Network [HPTN] 043) is
a large, Phase III, community-randomized, HIV prevention trial
conducted in 34 communities in Africa (in Soweto and Vulindlela,
South Africa; Tanzania; and Zimbabwe) and 14 communities in
Thailand (NCT00203749) [1–3]. Communities were matched in
pairs; communities in the intervention arm received enhanced
community-based voluntary counseling and testing services;
control communities received standard clinic-based volunteer
counseling and testing services [1]. These strategies were designed
to change community norms and reduce risk of HIV acquisition
among all community members, whether or not they participated
directly in the intervention. The intervention was delivered in each
community over three years (January 2006–May 2011). The
primary endpoint of the study was HIV incidence, assessed in a
single, cross-sectional, post-intervention survey of .50,000 indi-
viduals in the study communities (September 2009– July 2011).
To our knowledge, Project Accept is the first randomized
clinical trial with a primary cross-sectional HIV incidence
endpoint, and is one of the largest randomized clinical trials
performed to date. There were several reasons why a single, cross-
sectional survey was used to evaluate HIV incidence in Project
Accept. First, the study intervention included HIV testing; follow-
up of an HIV-uninfected cohort for HIV acquisition would have
required HIV testing in both control and intervention communi-
ties which would have confounded the ability to detect the effect of
the intervention. Second, use of a cross-sectional survey allowed
HIV incidence to be assessed in a larger, more representative
portion of the study population. Third, this approach avoided the
bias that may be associated with enrolling HIV-uninfected
participants and following them over time (e.g., from the
Hawthorne effect [4] or differential participant retention in
different study arms).
While there were inherent advantages to using a cross-sectional
approach to determine HIV incidence in Project Accept, this also
presented significant challenges. When the trial was originally
designed, the study plan was to assess HIV incidence using a single
HIV incidence assay, the BED capture immunoassay (BED-CEIA)
[5]. However, as the trial was being implemented in the field, it
became increasingly clear that the BED-CEIA significantly
overestimated HIV incidence in some settings. In 2006, the Joint
United Nations Programme on HIV/AIDS issued a statement
recommending against use of the BED-CEIA for HIV incidence
assessments [6]. Since there were no available methods that could
provide accurate cross-sectional HIV incidence estimates, the
HPTN Network Laboratory and the Project Accept statisticians
took on the challenge of developing alternate methods for cross-
sectional HIV incidence estimation (see below). The Project
Accept trial also presented significant challenges related to the size
of the study. New methods were developed to manage the large
number of study samples and to confirm the accuracy of HIV
testing performed at local in-country laboratories. A pilot study
that included approximately 2,500 participants was conducted at
additional, non-study communities across the five study sites to
develop, test, and optimize these procedures before they were
implemented for the primary study endpoint assessment [7].
The methods developed for cross-sectional HIV incidence
estimation in Project Accept are based on use of a multi-assay
algorithm (MAA) to identify infections that are potentially recent
(i.e., MAA positive) [4]. A MAA developed for cross-sectional HIV
incidence in subtype B epidemics has been shown to provide
accurate incidence estimates in clinical cohort studies performed in
the United States [4,8–10]. That MAA uses four biomarkers for
HIV incidence estimation: two serologic biomarkers (the BED-
CEIA and an avidity assay [11]) and two non-serologic biomarkers
(CD4 cell count and HIV viral load). These assays can be
performed using in a hierarchical approach to reduce the cost and
effort required for the analysis [12].
This report describes the methods used to determine HIV
prevalence and HIV incidence in Project Accept. It includes a
description of in-country testing of study samples, and quality
control testing performed at the HPTN Network Laboratory to
confirm the accuracy of in-country test results and determine/
confirm the HIV status of study participants. Laboratory data
were used to determine HIV prevalence and incidence. Because
HIV prevalence was lower than expected at the site in Thailand,
Table 1. Sample collection and in-country laboratory analysis.
Thailand Tanzania Zimbabwe
Soweto South
Africa
Vulindlela
South Africa Africa (4 sites)
Eligible participantsa 8,041 9,974 12,666 14,682 12,139 49,461
Participants with blood samplesb 7,619 9,041 11,880 13,929 11,843 46,693
HIV NEG 7,502 8,312 10,313 11,922 8,148 38,695
HIV DISC 39 187 19 22 46 274
HIV POS 78 542 1,548 1,985 3,649 7,724
Initial estimate of HIV prevalencec 1.02% 5.99% 13.0% 14.3% 30.8% 16.5%
aExcludes participants who were not contacted, declined participation, or did not meet enrollment criteria.
bSamples were not obtained for 2,744 eligible participants (2,310 no consent, 439 blood draw failure, 19 excluded for other reasons). The HIV status of study
participants was initially characterized based on the results of the two HIV rapid tests performed in-country (see Methods): HIV POS: two reactive HIV rapid tests. HIV
DISC: one reactive and one non-reactive HIV rapid test. HIV NEG: two non-reactive HIV rapid tests.
cAn initial estimate of HIV prevalence was based on in-country testing (calculated as # HIV POS samples/total # samples6100).
doi:10.1371/journal.pone.0068349.t001
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HIV incidence was estimated only for the four African sites. HIV
incidence was estimated using a MAA that included the same four
biomarkers as the MAA developed for subtype B (BED-CEIA,
avidity assay, CD4 cell count, and HIV viral load), but used assay
cutoffs that were optimized for analysis of HIV incidence in
populations with HIV subtypes that are prevalent in South Africa,
Zimbabwe, and Tanzania [13–16]. The overwhelming majority of
HIV infections in South Africa and Zimbabwe are subtype C; in
Tanzania, while most infections are subtype C, subtype A and D
infections are also observed [16]. The BED-CEIA and the avidity
assay used in the MAA frequently misclassify individuals with
long-standing subtype D HIV infection as potentially recently
infected [17,18]. To address this, a subset of the Project Accept
samples from Tanzania was subtyped to determine the prevalence
of subtype D in those communities and assess its potential impact
on incidence estimates. This report presents incidence estimates
for the Project Accept sites in Africa. The primary result of the
Project Accept trial (comparison of HIV incidence in control vs.
intervention communities) is presented in a separate report [19].
Materials and Methods
Ethics Statement
Written informed consent was obtained from all participants for
participation in Project Accept. Human experimentation guide-
lines of the US Department of Health and Human Services and
those of the authors’ institution(s) were followed in the conduct of
this research. The Project Accept study was approved by ethical
review committees for the study sites (South Africa: the University
of the Witwatersrand, Human Research Ethics Committee
[Medical]; Tanzania: the Muhimbili University of Health and
Allied Sciences [MUHAS] Senate Research and Publication
Committee and the National Institute of Medical Research Ethics
Committee; Zimbabwe: the Medical Research Council of
Zimbabwe; Thailand: the Ministry of Public Health Ethical
Review Committee of Research in Human Subjects [MOPHEC]
and the Human Experimentation Committee Research Institute
for Health Sciences, Chiang Mai University), and at collaborating
institutions in the United States (the Committee on Human
Research, University of California, San Francisco; the UCLA
Office of the Human Research Protection Program (OHRPP); the
Johns Hopkins University Bloomberg School of Public Health
Institutional Review Board; the Medical University of South
Carolina, Institutional Review Board for Human Research).
Source of Study Samples
Criteria for inclusion of participants in the post-intervention
assessment survey of Project Accept are described elsewhere [1].
Briefly, participants were selected from all community residents by
randomly sampling households in the study community. All
eligible household members aged 18–32 years were invited to
participate. Each participant provided blood samples for in-
country HIV testing and CD4 cell count testing. Stored plasma
aliquots were used for further analyses.
In-country Testing
HIV testing was performed at local laboratories, as previously
described [7]. Two HIV rapid tests were performed in parallel.
Samples were classified as HIV POS (both rapid tests reactive),
HIV DISC (one rapid test reactive, one rapid test non-reactive), or
HIV NEG (both rapid tests non-reactive). These terms (HIV POS,
HIV DISC, HIV NEG) were used to distinguish between the
initial classification of samples based solely on HIV rapid testing
Figure 1. Algorithms used for quality assurance testing of study samples. The figure illustrates the testing algorithms that were used to
determine and/or confirm the HIV status of study samples. This quality assurance testing was performed at the HPTN Network Laboratory (see
Methods). The algorithm used for quality assurance testing was determined by results obtained from HIV rapid testing performed at the study sites
(for samples initially designated as HIV NEG, HIV DISC, and HIV POS, see Methods). Quality assurance testing was performed for HIV POS samples if
results from the avidity assay suggested absent or very low levels of anti-HIV antibodies (weird avidity). In this case, the HIV DISC algorithm was used
to determine HIV status. Neg indicates that a negative or non-reactive test result was obtained. Pos indicates that a positive or reactive test result was
obtained. Arrows (non-bolded) indicate the next step in sample testing. The following abbreviations were used to describe assays and tests used in
the analysis (see Methods): HIV Combo: ARCHITECTH HIV Ag/Ab Combo assay; EIA: Vitros EIA Human Immunodeficiency Virus Type 1 and/or 2 (HIV-1/
2) Antibody Detection in Human Serum and Plasma; GA RNA: APTIMAH HIV-1 RNA Qualitative Assay; WB: Genetics System HIV-1 Western Blot.
doi:10.1371/journal.pone.0068349.g001
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and the final classification of HIV infection status. A CD4 cell
count was performed for all HIV POS and HIV DISC samples.
HPTN Network Laboratory Testing
Samples were shipped to the HPTN Network Laboratory at the
Johns Hopkins University School of Medicine (Baltimore, MD) for
further testing. Quality assurance testing was performed to
confirm the results of in-country HIV testing and to determine
the HIV status of HIV DISC samples; assays used for this testing
included: the Vitros EIA Human Immunodeficiency Virus Type 1
and/or 2 (HIV-1/2) Antibody Detection in Human Serum and
Plasma (VITROS ECi/ECiQ Immunodiagnostic System, Ortho
Diagnostics, Johnson & Johnson, Pencoed, United Kingdom), the
Genetics System HIV-1 Western Blot (BioRad Laboratories,
Redmond WA), and the APTIMAH HIV-1 RNA Qualitative
Assay (Gen-Probe Inc., San Diego, CA). A subset of the HIV NEG
samples was tested using the ARCHITECTH HIV Ag/Ab Combo
assay (HIV Combo; List: 2P36; Abbott Diagnostics, Wiesbaden,
Germany). The HIV Combo assay was performed only once;
reactive samples were evaluated further using additional assays
listed above.
Further testing to assess HIV incidence was performed using the
BED-CEIA (Calypte Biomedical Corporation, Lake Oswego, OR)
[5] and an avidity assay based on the Genetic Systems HIV-1/
HIV-2 Plus O EIA (Bio-Rad Laboratories, Redmond, WA) [11].
Results from the BED-CEIA and avidity assays were reported as
normalized optical density units (OD-n) and avidity index (%),
respectively. Viral load testing was performed for a subset of study
samples (Roche AMPLICOR HIV-1 MONITOR test, version
1.5, Roche Diagnostics, Indianapolis, IN). Samples were consid-
ered to be MAA positive if they had all of the following test results:
BED-CEIA ,1.2 OD-n, avidity index ,90%, CD4 cell count
Figure 2. Investigation of sample cross-contamination at a study site. The figure shows two examples of results from two Western blot runs
that were performed at the central laboratory as part of an investigation of discordant test results. Results from various laboratory tests are shown
above the Western blot strips. HIV rapid tests were performed at a laboratory at the study site in Soweto, South Africa using whole blood; N indicates
that both rapid tests were non-reactive, R indicates that both rapid tests were reactive. Samples were subsequently processed to produce plasma
aliquots for storage which were later shipped to a central laboratory in the United States for analysis. Results from the ARCHITECT Combo HIV Ag/Ab
test are shown (COMBO); N indicates that the Combo test was non-reactive, R indicates the Combo test was reactive. Samples were also tested using
the Vitros EIA Human Immunodeficiency Virus Type 1 and/or 2 (HIV-1/2) Antibody Detection in Human Serum and Plasma (EIA); N indicates that the
EIA test was non-reactive, R indicates the EIA test was reactive. Western blots were interpreted as negative (N) or positive (P) based on the pattern of
bands observed. The banding pattern typically varies among different HIV-positive samples. The panel on the left shows that samples 11–15 were
likely to have been cross-contaminated by transfer of plasma from sample 10 into those samples during aliquot preparation (sequential unintended
transfer of plasma from tube to tube). Similar findings are shown in the panel on the right; samples 17–19 were likely to have been cross-
contaminated by transfer of plasma from sample 16 into those samples. Further investigation at the study site confirmed that a technologist working
at the study site prepared sample aliquots without changing pipette tips. All of the samples that may have been processed on the days that this
technologist was working in the laboratory were excluded from the endpoint analysis.
doi:10.1371/journal.pone.0068349.g002
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.200 cells/mm3, and HIV viral load .400 copies/ml; this MAA
has a mean window period of 259 days in subtype A and C
epidemics [14]. HIV subtypes were determined for a subset of
samples from Tanzania by phylogenetic analysis of HIV gag and
gp41 sequences (GenBank accession numbers: KC589446–
KC589569 [Gag] and KC589570–KC589696 [gp41]) [20].
Selected plasma samples were tested for the presence of ARV
drugs [21]. Samples were analyzed using a qualitative, high-
resolution accurate mass spectrometric method developed to
detect 15 ARV drugs, including protease inhibitors (PIs: ampre-
navir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir,
ritonavir, saquinavir, and tipranavir), non-nucleotide reverse
transcriptase inhibitors (NNRTIs: efavirenz, nevirapine), and
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs:
emtricitabine, lamivudine, tenofovir). Detailed methods are
described in the legend for Tables S1 and S2 in File S1.
Data Management
The Laboratory Data Management System (LDMS, Frontier
Science & Technology Research Foundation, Inc.) was used to
track specimen collection, testing, storage, and shipping. Data
from study sites and in-country laboratories were submitted to the
Project Accept Statistical Center. After those data were merged
and reviewed, they were submitted to the HPTN Statistical and
Data Management Center (SDMC). Data from the HPTN
Network Laboratory were submitted directly to the HPTN
SDMC.
Results
In-country Testing
In Project Accept, 46,693 (94.4%) of 49,461 eligible participants
provided blood samples for analysis (Table 1). Samples were
initially classified as HIV POS, HIV DISC, or HIV NEG based on
results from two HIV rapid tests (see Methods). CD4 cell count
testing was performed for HIV POS and HIV DISC samples.
Overall, 7,724 samples were HIV POS, 274 were HIV DISC, and
38,695 were HIV NEG (Table 1). The initial prevalence estimate
based on in-country testing was 16.5% (1.02% in Thailand, 5.99%
to 30.8% at the four African sites, Table 1). All HIV POS and
HIV DISC samples and a subset of HIV NEG samples were
shipped to the HPTN Network Laboratory for further analysis.
The number of incident infections identified in Thailand was too
low to contribute to the endpoint assessment (3 incident infections
Table 2. Quality assurance testing.
Tanzania Zimbabwe
Soweto South
Africa
Vulindlela South
Africa Total
Quality assurance testing of HIV NEG samplesa
Tested with HIV Combo (%)b 1,932 1,999 2,900 2,910 9,741
Combo reactive 15 (0.78%) 7 (0.35%) 65 (2.24%) 23 (0.79%) 110 (1.13%)
HIV POS and HIV DISC samples censored (among those originally classified as HIV POS or HIV DISC)
Excluded due to contamination 0 0 292 0 292
Excluded for other reasonsc 0 1 23 4 28
Classification of HIV DISC samplesa
Samples remaining after exclusions 187 19 20 46 272
HIV uninfected 184 18 18 45 265
HIV infected 3 1 2 1 7
Acute infection 1 0 0 0 1
Early infection 0 0 0 0 0
Established infection 2d 1d 2e 1e 6
Classification of HIV POS samplesa
Samples remaining after exclusions 542 1,547 1,672 3,645 7,406
HIV uninfected 9 17 22 4 52
HIV infected 533 1,530 1,650 3,641 7,354
Acute infection 0 0 0 3 3
Early infection 1 0 0 2 3
Established infection 532 1,530 1,650 3,636 7,348
Abbreviations: WB: Western blot; HIV Combo: ARCHITECT HIV Ag/Ab Combo assay.
aThe HIV status of study participants was initially characterized based on the results of the two HIV rapid tests performed in-country (see Methods): HIV POS: two
reactive HIV rapid tests. HIV DISC: one reactive and one non-reactive HIV rapid test. HIV NEG: two non-reactive HIV rapid tests. The testing algorithm used to confirm the
HIV status of HIV NEG and HIV DISC samples (quality assurance testing) are shown in Figure 1. Quality assurance testing was only performed for HIV POS samples if
results from the avidity assay suggested absent or extremely low levels of anti-HIV antibodies.
bThis indicates the number of samples that had reactive results using the HIV Combo assay (signal/cutoff .1). According to the package insert, specimens that are
initially reactive with HIV Combo should be retested in duplicate and only repeatedly reactive specimens are considered reactive. In this study, samples were analyzed
only once using the HIV Combo assay.
c28 samples were excluded for reasons other than contamination, including: no CD4 cell count obtained (N = 5); insufficient quantity of plasma stored for testing (N = 2);
failure of sample tracking (N = 17); protocol violation (N = 4).
dThese three samples were subsequently classified as MAA positive.
eThese three samples were subsequently classified as MAA negative.
doi:10.1371/journal.pone.0068349.t002
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in 14 matched communities). Therefore, the endpoint assessment
was limited to the four African sites.
Analysis of HIV NEG Samples
For quality assurance, the first two batches of HIV NEG
samples received at the HPTN Network Laboratory from each
study site were tested using the automated, fourth generation HIV
screening assay (HIV Combo, see Methods; Figure 1). Non-
reactive test results were obtained for 9,631 (98.9%) of the
9,741 HIV NEG samples tested, confirming that the participants
were HIV-uninfected; the remaining 110 samples had reactive test
results (Table 2). A high proportion of the reactive samples (59% of
the 110 samples) were from Soweto (2.24% of the HIV NEG
samples from Soweto were reactive, compared to 0.35–0.79% at
the other three African study sites). The high frequency of reactive
test results from this site prompted an investigation that revealed
that a technologist working at site did not change pipette tips while
preparing plasma aliquots (Figure 2). Based on these findings, HIV
Combo testing was performed for all HIV NEG samples from
Soweto that were processed during the period when the
technologist was employed in the laboratory. The following
approach was used to exclude samples that may have been
contaminated: (1) the technologist was on duty that day and at
least one HIV NEG sample had a reactive HIV Combo test, or (2)
the technologist was not on duty that day (or it could not be
determined whether the technologist was on duty), and at least two
HIV NEG samples had reactive HIV Combo tests. Note that all
samples meeting these criteria were excluded, regardless of their
original designation (HIV POS, HIV DISC, or HIV NEG).
Overall, this process resulted in excluding 1,710 HIV NEG
samples and 292 samples that were either HIV POS or HIV
DISC. After excluding for contamination, 58 (0.62%) of
9,314 HIV NEG samples were HIV Combo reactive, including
0.43% of the HIV NEG samples from Soweto. Those samples
were analyzed further using the testing algorithm shown in
Figure 1; 44 were classified as HIV negative, seven were classified
as acute infections (HIV RNA positive, HIV antibody negative),
one was classified as early HIV infection (HIV RNA positive, EIA
positive, Western blot indeterminate), and six were classified as
established HIV infections (Western blot positive). Note that
samples originally classified as HIV NEG were analyzed for
quality assurance only; results from these samples were not used in
the endpoint assessment.
Analysis of HIV DISC Samples
A total of 272 HIV DISC samples remained after sample
exclusion (see above, Table 2). These samples were analyzed using
the testing algorithm shown in Figure 1; 265 (97.4%) of the
samples were confirmed to be from individuals who did not have
HIV infection. The remaining seven samples included one acute
infection and six established infections (Table 2).
Analysis of HIV POS Samples
Quality assurance testing of HIV POS samples was restricted to
samples with avidity assay results that suggested that HIV
antibodies were absent or present at very low levels. Those
samples were further analyzed using the testing algorithm for HIV
DISC samples (Figure 1); 52 of those samples (0.70% of
7,406 HIV POS samples) were from HIV-uninfected individuals.
This was consistent with the rate of false positive in-country test
results observed in the Project Accept pilot study (0.63%) [7]. The
remaining samples included three acute infections, three early
infections, and 7,348 established HIV infections (Table 2).
Analysis of HIV Subtype
We determined the frequency of subtype D infection at the
Project Accept site in Tanzania by testing 113 samples from that
site (at least 10 samples from each community, see Methods).
Overall, 9.7% of the samples were subtype D (with 44.3% subtype
A, 22.1% subtype C, and 23.9% intersubtype recombinant). The
highest prevalence of subtype D in a single community was 30%
(3/10), while three communities had no subtype D HIV among
the samples tested. Overall, 534 (7.26%) of the 7,354 established
infections in Project Accept were from Tanzania (Table 2). Based
on a subtype D prevalence of 9.7%, we estimated that only 0.7%
of the established infections in Project Accept would be subtype D.
Even if some of the non-recent subtype D infections were
misclassified as MAA positive, it would be unlikely to influence
overall HIV incidence estimated in the trial. There was no
Figure 3. Multi-assay algorithm (MAA) used for HIV incidence
estimation. Study samples were initially designated as HIV NEG, HIV
DISC, and HIV POS based on HIV rapid testing performed at study sites
(see Methods). HIV POS and HIV DISC samples (those that had at least
one reactive HIV rapid test) were further evaluated at the HPTN
Network Laboratory to determine the HIV status of each sample. The
majority of the HIV POS samples and some of the HIV DISC samples
were determined to be from individuals with established HIV infection
(Table 3). Those samples were analyzed further using a multi-assay
algorithm (MAA) developed for HIV incidence estimation. The figure
shows the MAA testing schema. Samples were initially tested with the
BED capture immunoassay (BED-CEIA) and an avidity assay. Samples
that had a BED-CEIA result $1.2 normalized optical density units (OD-n)
were considered to be MAA negative and were not evaluated further.
The remaining samples were evaluated based on results of the avidity
assay. Samples that had an avidity assay result (avidity index) $90%
were considered to be MAA negative and were not evaluated further.
The remaining samples were evaluated based on results of CD4 cell
count testing that was performed at study sites around the time of
sample collection (CD4). Samples that had CD4 cell count result ,200
cells/mm3 were considered to be MAA negative and were not evaluated
further; if a CD4 cell count result was not obtained at the time of sample
collection, recency could not be assessed. The remaining samples were
tested using an HIV viral load assay (VL). Samples that had a viral load
result ,400 copies/mL were considered to be MAA negative and were
not evaluated further. Samples that met all of the criteria for the MAA
(BED-CEIA ,1.2 OD-n+avidity index ,90%+CD4 cell count .200 cells/
mm3+ HIV viral load .400 copies/mL) were classified as MAA positive.
doi:10.1371/journal.pone.0068349.g003
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significant difference in the performance of the BED-CEIA and
avidity assay with subtypes A and C in our validation studies [15].
HIV Incidence Assessment
Results from in-country and quality assurance testing identified
7,361 confirmed HIV infections in Project Accept, including four
acute infections, three early infections, and 7,354 established
infections (Table 3). The 7,354 samples from participants with
established infections were analyzed using the MAA (see Methods,
Figure 3). For this analysis, all 7,354 samples were tested with the
BED-CEIA and the avidity assay. HIV viral load testing was only
performed for samples that had a BED-CEIA result ,1.2 OD-n,
an avidity index ,90%, and a CD4 cell count .200 cells/mm3.
This evaluation identified 467 MAA positive samples (Table 3).
In resource-limited settings, individuals with recent HIV
infection are often not aware of their HIV status; even if they
are, they are not likely to initiate ARV treatment until later in the
course of their disease. For this reason, ARV treatment has been
used as a surrogate marker of long-standing HIV infection in some
settings [22]. As a final step in our incidence assessment, samples
classified as MAA positive were tested for the presence of ARV
drugs; this testing was performed using a high-throughput,
qualitative ARV drug screen that includes ARV drugs available
in the study countries at the time that the trial was performed
(Table 4) [21]. ARV test results were obtained for 461 (98.7%) of
the 467 MAA positive samples; 29 (6.7%) of those samples had at
least one ARV drug detected and were not included in the primary
endpoint assessment, leaving a total of 439 infections classified as
incident (Table 3). For comparison, we also tested all 88 samples
that were classified as MAA negative solely on the basis of viral
suppression (i.e., samples with BED-CEIA ,1.2 OD-n, avidity
index ,90%, CD4 cell count .200 cells/mm3, and HIV viral
Table 3. Final sample classification, HIV prevalence, and estimated annual HIV incidence.
Tanzania Zimbabwe
Soweto South
Africa
Vulindlela
South Africa Total/Overall
Final sample classification (among those originally designated as HIV DISC or HIV POS)a
HIV-uninfected 193 35 40 49 317
HIV-infected 536 1,531 1,652 3,642 7,361
Acute infection 1 0 0 3 4
Early infection 1 0 0 2 3
Established infection 534 1,531 1,652 3,637 7,354
MAA negative 479 1,461 1,547 3,400 6,887
MAA positiveb 55 70 105 237 467
ARV drug(s) detected 10 3 4 12 29
No ARV drugs detected 45 66 101 220 432
Not tested/no resultc 0 1 0 5 6
Total incident infectionsd 47 67 101 230 445
HIV Prevalence
HIV prevalence 5.9% 12.9% 14.1% 30.8% 16.5%
Annual Incidence Estimate
HIV incidence 0.78% 0.91% 1.18% 3.90% 1.60%
Abbreviations: MAA: multi-assay algorithm; ARV: antiretroviral drug.
aThe HIV status of study participants was initially characterized based on the results of the two HIV rapid tests performed in-country (see Methods). The testing
algorithms used to classify samples according to HIV infection status are shown in Figures 1 and 2.
bSamples classified as MAA positive (see Figure 1) were tested for the presence of ARV drugs (see text).
cTwo samples did not have sufficient volume remaining for testing and four samples failed testing; these were included in the analysis as incident infections.
dIncident infections include acute infections, early infections (confirmed infections with indeterminate Western blots), and established infections classified MAA positive
(see Figure 2) that either had no ARV drugs detected or no ARV test result (shown in bold).
doi:10.1371/journal.pone.0068349.t003
Table 4. Detection of antiretroviral drugs in study samples.
ARV drugs detected
Sample type N Female No drugs 1 drug $2 drugs
MAA positive (within the window
period for recent infection using
the MAA)
461 311 (67.5%) 432 (93.7%) 26 (5.6%) 3 (1.1%)
MAA negative, excluded from the
window period for recent infection
based solely on low viral load
88 65 (73.9%) 31 (64.8%) 12 (13.6) 45 (51.1%)
Abbreviations: ARV: antiretroviral; MAA: multi-assay algorithm; N: number of samples/participants.
doi:10.1371/journal.pone.0068349.t004
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load ,400 copies/ml); 57 (64.8%) of the 88 samples in this group
had at least one ARV drug detected (Table 4). Detailed results of
ARV drug testing are provided in Tables S1 and S2 in File S1.
Based on the analysis described above, the overall HIV
prevalence in Project Accept was 16.5%, with a range from
5.93% in Tanzania to 30.8% in Vulindlela, South Africa (Table 3).
These prevalence rates are very similar to the initial prevalence
rates determined solely by in-county HIV rapid testing (Table 1).
In the HIV incidence assessment, the following infections were
classified as incident: acute infections (N= 4), early infections
(N= 3) and infections that were classified as MAA positive that
either had no ARV drugs detected or had no ARV test result
(N= 438); overall, 455 incident infections were identified.
The overall annual HIV incidence in the Project Accept was
1.60%, with a range from 0.78% in Tanzania to 3.90% in
Vulindlela, South Africa (Table 3).
Discussion
The assessment of HIV incidence in Project Accept began by
determining the HIV status of each study participant. As a first
step, samples were tested in-country using two HIV rapid tests
performed in parallel. Quality assurance testing was performed at
a central laboratory. In general, quality assurance testing
confirmed the results of in-country HIV rapid testing. Notably,
quality assurance testing identified a problem with sample
processing at one study site that resulted in cross-contamination
of numerous sample aliquots. As a result, a significant portion of
the samples from the site in Soweto, South Africa was excluded
from the endpoint analysis. This finding emphasizes the impor-
tance of rigorous quality assurance testing.
Samples that were confirmed to be from participants with HIV
infection were further characterized based on the stage of HIV
infection (acute, early, or established infection). Acute and early
HIV infections were considered to be incident infections. Very few
acute HIV infections were identified in this study (among 9,269
samples with non-reactive HIV rapid tests, only 7 acute infections
were identified using a 4th generation screening assay). This
emphasizes the limitation of using acute HIV infection for
incidence determination [23].
Samples from individuals with established infection were
analyzed further using a MAA that was optimized for incidence
estimation in Project Accept; development and validation of this
MAA is described in two previous reports [14,15]. This MAA has
a mean window period of 259 days and was shown in validation
studies to provide sufficient power to detect a 35% decrease in
HIV incidence in the intervention communities of Project Accept
[14,15]. Our previous reports also demonstrate that this MAA has
an overall precision that is comparable or better than incidence
estimates based on a simulated cohort follow-up study of 6-months
duration [14,15]. One consideration in the development of this
MAA was HIV subtype. Previous studies have shown that
individuals with long-standing HIV subtype D infection are
frequently misclassified by serologic assays as potentially recently
infected [15,17]. The MAA used in this study was optimized for
analysis of HIV incidence in subtypes A and C [14,15]. Because
subtype D HIV is known to circulate in Tanzania, we determined
the prevalence of subtype D HIV at the Project Accept site in
Tanzania. Fortunately, the prevalence of subtype D at that site was
low (9.7%) and was unlikely to impact the incidence assessment in
the trial.
Another potential confounder in cross-sectional HIV incidence
estimation is antiretroviral treatment (ART). Prolonged ART is
associated with down-regulation of the anti-HIV antibody
response, which can affect the performance of serologic incidence
assays [18,24]. The MAA used in this study characterizes
individuals who are virally suppressed as MAA negative. However,
even in the absence of viral suppression, ART may serve as a
useful surrogate for non-recent HIV infection, since individuals are
unlikely to initiate ART in the first few months after infection. For
this reason, we tested samples that were classified as MAA positive
for the presence of antiretroviral drugs; 29 (6.7%) of the 467 MAA
positive samples had one or more antiretroviral drugs detected and
were excluded from the incidence analysis. The infrequent
detection of antiretroviral drugs in the MAA positive samples
provides further support for use of the MAA to identify recent
HIV infection; notably, 64.8% of the samples that met three of the
four criteria of the MAA but had undetectable HIV RNA (,400
copies/mL) contained antiretroviral drugs. It is notable that a
significant proportion (35.2%) of those did not contain antiretro-
viral drugs; those samples, which represented 0.42% of the 7,354
samples analyzed with the MAA, were most likely from elite
controllers. Note that the MAA classifies all samples with low viral
load as MAA negative (regardless of whether antiretroviral drugs
are present), which is important, since elite controllers can be
misclassified as recently infected using serologic incidence assays
[24].
This study provides a model for cross-sectional estimation of
HIV incidence in a large, randomized clinical study. This
approach is likely to become more widely used, as HIV prevention
trials move from longitudinal studies of HIV-uninfected cohorts to
larger, community-randomized trials of combination prevention
interventions delivered to entire populations. Strict attention to the
quality of laboratory test results, and rigorous validation of testing
algorithms for cross-sectional incidence estimation using large
validation sample sets from relevant study populations are critical
elements for this type of analysis.
Supporting Information
File S1 Table S1, Antiretroviral drugs detected by drug class
among samples that were classified as MAA positive using the
multi-assay algorithm. Table S2, Antiretroviral drugs detected by
drug class among samples that were classified as MAA negative
using the multi-assay algorithm solely on the basis of HIV viral
load #400 copies/ml.
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